局部晚期胰腺癌放化疗患者生存预测列线图的建立
基于2004至2015年间426例接受同步放化疗的局部晚期胰腺癌患者,研究利用FDG-PET参数(SUVmax)和CA 19-9水平建立生存预测列线图。中位随访15个月时,中位无进展生存期和总生存期分别为9.4个月和15.4个月。多因素分析显示高剂量放疗(EQD2≥61 Gy)、初始SUVmax<3.5、CA 19-9≤400 U/mL及放化疗后手术切除与总生存期延长显著相关(p<0.05),列线图区分度c-index为0.656,可将患者分为三组,中位总生存期分别为25、15和11个月(p<0.001)。
要点
- 高剂量放疗(EQD2≥61 Gy)、初始SUVmax<3.5、CA 19-9≤400 U/mL及放化疗后手术切除与总生存期延长显著相关(p<0.05)。
- 列线图区分度c-index为0.656,可将患者分为三组,中位总生存期分别为25、15和11个月(p<0.001)。
- 列线图有助于临床决策和筛选适合放化疗的患者。
核心结论
- 基于高剂量放疗(EQD2≥61 Gy)、初始SUVmax<3.5、CA 19-9≤400 U/mL和放化疗后手术切除建立了局部晚期胰腺癌患者的列线图,有助于临床决策和筛选适合放化疗的患者。
研究设计与样本
- 基于2004至2015年间426例接受同步放化疗的局部晚期胰腺癌患者,研究显著预后因素以建立列线图,包括SUVmax和CA 19-9水平。
主要发现
- 中位随访15个月时,中位无进展生存期和总生存期分别为9.4个月和15.4个月。
- 多因素分析显示高剂量放疗(EQD2≥61 Gy)、初始SUVmax<3.5、CA 19-9≤400 U/mL及放化疗后手术切除与总生存期延长显著相关(p<0.05)。
- 列线图模型校准良好,区分度可接受(c-index 0.656)。
- 使用列线图可识别3个不同预后组,中位总生存期分别为25、15和11个月(p<0.001)。
关键数值与推荐
- 高剂量放疗定义为EQD2≥61 Gy。
- 初始SUVmax<3.5和CA 19-9≤400 U/mL为预后因素。
- 放化疗后手术切除与总生存期延长显著相关(p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We developed a nomogram for predicting survival of patients with locally advanced pancreatic cancer (LAPC) after concurrent chemoradiotherapy (CRT) using 18F-flurodeoxyglucose-positron emission tomography (FDG-PET) parameters and CA 19-9 levels. METHODS: Based on 426 patients with LAPC who received concurrent CRT between 2004 and 2015, we investigated significant prognostic factors for survival to build a nomogram, including the maximum standardized uptake value (SUVmax) and CA 19-9 levels. Predictive accuracy and discriminative ability were then measured. RESULTS: Median progression-free survival and overall survival (OS) were 9.4 and 15.4 months, respectively, at a median 15-month follow-up. High-dose radiation (EQD2, ≥61 Gy), initial SUVmax <3.5 and CA 19-9 ≤400 U/mL, and surgical resection after CRT were significantly related to prolonged OS by multivariate analysis (p < 0.05). A nomogram model for OS was established and showed good calibration and acceptable discrimination (c-index 0.656). Using the nomogram, 3 different prognosis groups could be identified with a median OS of 25, 15, and 11 months (p < 0.001). CONCLUSION: A nomogram was developed with high-dose radiation (EQD2, ≥61 Gy), initial SUVmax <3.5, CA 19-9 ≤400 U/mL, and surgical resection after CRT for patients with LAPC. This will help in clinical decision-making and in selecting patients for CRT.
引用
- Choi SH, Park SW, Seong J, et al. A nomogram for predicting survival of patients with locally advanced pancreatic cancer treated with chemoradiotherapy. Radiother Oncol. 2018. PMID: 30177371. doi:10.1016/j.radonc.2018.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。